This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Twenty-four hours later, my brain is still whirling over yesterday’s stunning news from Merck and Moderna about the success of their personalized mRNA cancer therapy in a melanoma late-stage clinical trial.
I posted this on X yesterday but it’s worth repeating here: Between this spring’s Revolution Medicines success with a KRAS-targeted drug and now Merck and Moderna’s success with an mRNA neoantigen vaccine, 2026 will go down as one of the most consequential years in cancer treatment, ever.